arsenic trioxide has been researched along with cudc 101 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, Q; Lu, T; Ma, D; Wang, J; Wang, W; Wei, D; Yu, K; Zhang, T; Zhang, Z | 1 |
1 other study(ies) available for arsenic trioxide and cudc 101
| Article | Year |
|---|---|
CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Biomarkers, Tumor; Caspases; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Prognosis; Quinazolines; Retinoic Acid Receptor alpha; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |